Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD
patients and to assess the influence of Px-104 on hepatic fat.